二甲双胍通过STAT1增强脂肪间充质干细胞免疫调节能力治疗狼疮动物模型
本研究在MRL/lpr狼疮小鼠模型中探讨二甲双胍能否增强脂肪间充质干细胞的免疫调节功能及其机制。体外实验显示二甲双胍通过AMPK/mTOR通路上调STAT1,促进IDO、IL-10和TGF-β表达;体内输注二甲双胍处理的Ad-MSCs可显著改善小鼠疾病活动。
要点
- 二甲双胍通过AMPK/mTOR/STAT1通路增强Ad-MSCs的免疫调节因子表达。
- 二甲双胍处理的Ad-MSCs可改善MRL/lpr小鼠肾炎、蛋白尿及抗dsDNA抗体。
- 该处理抑制CD4-CD8- T细胞扩增并降低Th17/Treg细胞比值。
核心结论
- 二甲双胍优化了脂肪间充质干细胞的免疫调节特性,可能成为治疗狼疮的新型治疗剂。
研究设计与样本
- 体外用二甲双胍培养Ad-MSCs 72小时,检测免疫调节因子表达及信号通路。
- MRL/lpr小鼠每周静脉注射1×10^6 Ad-MSCs或二甲双胍处理的Ad-MSCs,持续8周,16周龄时处死分析。
主要发现
- 二甲双胍增强Ad-MSCs的IDO、IL-10和TGF-β表达。
- 二甲双胍上调Ad-MSCs中p-AMPK和p-STAT1,抑制p-STAT3和p-mTOR表达。
- STAT1 siRNA抑制后,二甲双胍处理的Ad-MSCs中IDO、IL-10、TGF-β显著减少。
- 输注二甲双胍处理的Ad-MSCs显著改善MRL/lpr小鼠炎症表型、肾小球肾炎、蛋白尿和抗dsDNA IgG抗体产生。
- 二甲双胍处理的Ad-MSCs抑制CD4-CD8- T细胞扩增并降低Th17/Treg细胞比值。
临床怎么用
- 在狼疮动物模型中,二甲双胍预处理可增强Ad-MSCs的免疫抑制功能,改善疾病活动,提示联合策略的潜在价值。
局限性
- 研究仅基于MRL/lpr小鼠模型和体外细胞实验,尚未在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Mesenchymal stem cells (MSCs) are considered potential therapeutic agents for treating autoimmune disease because of their immunomodulatory capacities and anti-inflammatory effects. However, several studies have shown that there is no consistency in the effectiveness of the MSCs to treat autoimmune disease, including SLE. In this study, we investigated whether metformin could enhance the immunoregulatory function of MSCs, what mechanism is relevant, and whether metformin-treated MSCs could be effective in an animal lupus model. METHODS: Adipose-derived (Ad)-MSCs were cultured for 72 h in the presence of metformin. Immunoregulatory factors expression was analysed by real-time PCR and ELISA. MRL/lpr mice weekly injected intravenously with 1 × 106 Ad-MSCs or metformin-treated Ad-MSCs for 8 weeks. 16-week-old mice were sacrificed and proteinuria, anti-dsDNA IgG antibody, glomerulonephritis, immune complex, cellular subset were analysed in each group. RESULTS: Metformin enhanced the immunomodulatory functions of Ad-MSCs including IDO, IL-10 and TGF-β. Metformin upregulated the expression of p-AMPK, p-STAT1 and inhibited the expression of p-STAT3, p-mTOR in Ad-MSCs. STAT1 inhibition by siRNA strongly diminished IDO, IL-10, TGF-β in metformin-treated Ad-MSCs. As a result, metformin promoted the immunoregulatory effect of Ad-MSCs by enhancing STAT1 expression, which was dependent on the AMPK/mTOR pathway. Administration of metformin-treated Ad-MSCs resulted in significant disease activity improvement including inflammatory phenotype, glomerulonephritis, proteinuria and anti-dsDNA IgG antibody production in MRL/lpr mice. Moreover, metformin-treated Ad-MSCs inhibited CD4-CD8- T-cell expansion and Th17/Treg cell ratio. CONCLUSION: Metformin optimized the immunoregulatory properties of Ad-MSCs and may be a novel therapeutic agent for the treatment of lupus.
引用
- Jang SG, Lee J, Hong SM, et al. Metformin enhances the immunomodulatory potential of adipose-derived mesenchymal stem cells through STAT1 in an animal model of lupus. Rheumatology (Oxford). 2020. PMID: 31904843. doi:10.1093/rheumatology/kez631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。